Atika Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.03M | Buy |
+27,700
| New | +$9.03M | 0.9% | 29 |
|
|
2024
Q4 | – | Sell |
-31,000
| Closed | -$8.53M | – | 76 |
|
|
2024
Q3 | $8.53M | Buy |
31,000
+6,500
| +27% | +$1.79M | 0.87% | 40 |
|
|
2024
Q2 | $5.95M | Buy |
+24,500
| New | +$5.95M | 0.58% | 53 |
|
|
2021
Q4 | – | Sell |
-64,000
| Closed | -$12.1M | – | 76 |
|
|
2021
Q3 | $12.1M | Buy |
+64,000
| New | +$12.1M | 0.72% | 48 |
|
|
2018
Q3 | – | Sell |
-23,000
| Closed | -$2.27M | – | 73 |
|
|
2018
Q2 | $2.27M | Sell |
23,000
-18,000
| -44% | -$1.77M | 0.44% | 58 |
|
|
2018
Q1 | $4.88M | Buy |
41,000
+16,000
| +64% | +$1.91M | 1.67% | 22 |
|
|
2017
Q4 | $3.18M | Hold |
25,000
| – | – | 1.23% | 35 |
|
|
2017
Q3 | $2.94M | Buy |
+25,000
| New | +$2.94M | 0.84% | 41 |
|
|
2016
Q4 | – | Sell |
-22,000
| Closed | -$1.49M | – | 56 |
|
|
2016
Q3 | $1.49M | Buy |
22,000
+8,000
| +57% | +$543K | 0.61% | 52 |
|
|
2016
Q2 | $777K | Buy |
+14,000
| New | +$777K | 0.33% | 52 |
|
|
2015
Q3 | – | Sell |
-24,000
| Closed | -$2.88M | – | 53 |
|
|
2015
Q2 | $2.88M | Buy |
24,000
+18,500
| +336% | +$2.22M | 1.3% | 33 |
|
|
2015
Q1 | $574K | Buy |
+5,500
| New | +$574K | 0.38% | 54 |
|
|
2014
Q3 | – | Sell |
-20,000
| Closed | -$1.26M | – | 62 |
|
|
2014
Q2 | $1.26M | Buy |
+20,000
| New | +$1.26M | 1.03% | 40 |
|